{"id":4429,"date":"2021-09-11T15:42:44","date_gmt":"2021-09-11T19:42:44","guid":{"rendered":"https:\/\/www.wmfc.ca\/?p=4429"},"modified":"2021-09-21T11:22:33","modified_gmt":"2021-09-21T15:22:33","slug":"reduire-le-traitement-de-la-toxicite-chez-les-femmes","status":"publish","type":"post","link":"https:\/\/www.wmfc.ca\/fr\/2021\/09\/11\/reducing-treatment-toxicity-in-wm\/","title":{"rendered":"R\u00e9duire la toxicit\u00e9 des traitements pour le  MW"},"content":{"rendered":"<p>A propos de la <a href=\"https:\/\/www.waldenstroms.com\/images\/publications\/2021-7.pdf\" target=\"_blank\" rel=\"noopener\">publication r\u00e9cente d'une revue<\/a> des experts du Dana-Farber Cancer Institute de Boston r\u00e9sume les effets ind\u00e9sirables les plus courants qui surviennent pendant le traitement.  L'article a \u00e9t\u00e9 publi\u00e9 dans la revue \"Expert Opinion on Drug Safety\".<\/p>\n<p>Un encadr\u00e9 r\u00e9capitulatif dans la publication indique :<\/p>\n<ul>\n<li>Il existe plusieurs options efficaces et s\u00fbres pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m, bien que les patients doivent \u00eatre \u00e9troitement surveill\u00e9s pendant le traitement pour d\u00e9tecter l'apparition d'effets secondaires sp\u00e9cifiques au traitement.<\/li>\n<li>La r\u00e9duction du nombre de cycles de traitement par rituximab-bendamustine peut pr\u00e9venir la toxicit\u00e9 sans compromettre les r\u00e9sultats de la maladie.<\/li>\n<li>La fr\u00e9quence des doses de bort\u00e9zomib et le mode d'administration peuvent \u00eatre modifi\u00e9s pour diminuer le risque de neuropathie p\u00e9riph\u00e9rique chez les patients atteints de macroglobulin\u00e9mie de Waldenstr\u00f6m.<\/li>\n<li>Les patients atteints de macroglobulin\u00e9mie de Waldenstr\u00f6m pr\u00e9sentent un profil unique d'effets secondaires associ\u00e9s au rituximab, notamment un risque accru d'intol\u00e9rance au rituximab et de pouss\u00e9es d'IgM.<\/li>\n<li>L'ibrutinib est un traitement efficace de la macroglobulin\u00e9mie de Waldenstr\u00f6m avec un profil d'effets secondaires m\u00e9dicalement g\u00e9rable qui comprend la fibrillation auriculaire et les saignements.  Les nouveaux inhibiteurs de BTK, tels que le zanubrutinib et l'acalabrutinib, pr\u00e9sentent des niveaux d'activit\u00e9 similaires avec des diff\u00e9rences dans le profil des effets secondaires.<\/li>\n<\/ul>\n<p>Vous pouvez <a href=\"https:\/\/www.waldenstroms.com\/images\/publications\/2021-7.pdf\" target=\"_blank\" rel=\"noopener\">lire ou t\u00e9l\u00e9charger le document ici<\/a>.  Il peut \u00eatre utile lors des discussions avec votre oncologue\/h\u00e9matologue.<\/p>","protected":false},"excerpt":{"rendered":"<p>A recent review publication from the experts at the Dana-Farber Cancer Institute in Boston summarizes the most common adverse effects that occur during treatment.\u00a0 The article was published in the journal, &#8220;Expert Opinion on Drug Safety&#8221;. A summary box in the publication states: There are several\u00a0 effective\u00a0 and\u00a0 safe\u00a0 options\u00a0 for\u00a0 the\u00a0 treatment\u00a0 of Waldenstr\u00f6m macroglobulinemia although patients should be closely monitored\u00a0 during\u00a0 therapy\u00a0 for\u00a0 the\u00a0 emergence\u00a0 of\u00a0 treatment-specific side effects. Reduction in the\u00a0 number\u00a0 of\u00a0 rituximab-bendamustine\u00a0 treatment cycles may prevent toxicity without compromising disease outcomes. The frequency of bortezomib dosing and the manner of administration can be altered to decrease <a href=\"https:\/\/www.wmfc.ca\/fr\/2021\/09\/11\/reducing-treatment-toxicity-in-wm\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-4429","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=4429"}],"version-history":[{"count":3,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4429\/revisions"}],"predecessor-version":[{"id":4462,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4429\/revisions\/4462"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=4429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=4429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=4429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}